Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 3Completed 3Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 37Gastrointestinal 19Thoracic 11Tumor-Agnostic 9Other hematologic neoplasm 6Head & Neck 5CNS 5Breast 5Sarcoma 3Plasma cell 3Other solid neoplasm 3Endocrine 3Myeloid 2Gynecologic 2Lymphoid 1

Conditions

Solid Tumors 1Neoplasms 1Mesothelioma 1Advanced Malignant Solid Neoplasm 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × trametinib × Other solid neoplasm × Clear all
NCT01827384 2023-09-29

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

National Cancer Institute (NCI)

Phase 2 Completed
208 enrolled 27 charts
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT02705963 2022-02-09

A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

Novartis

Phase 1 Completed
19 enrolled
Other solid neoplasm

Solid Tumors

NCT01938443 2019-07-12

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

GlaxoSmithKline

Phase 1 Completed
34 enrolled
Other solid neoplasmThoracic

Mesothelioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡